| Comparative effectiveness and safety of interventions for acute diarrhea and gastroenteritis in children: a systematic review and network meta-analysis ID Florez, AA Veroniki, R Al Khalifah, JJ Yepes-Nunez, JM Sierra, ... PloS one 13 (12), e0207701, 2018 | 98 | 2018 |
| Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: systematic review and meta-analysis N Foroutan, S Muratov, M Levine Clinical and Investigative Medicine 39 (2), E48-E62, 2016 | 55 | 2016 |
| Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer’s disease: A systematic review and network meta-analysis N Foroutan, RB Hopkins, JE Tarride, ID Florez, M Levine Clinical and Investigative Medicine 42 (1), E53-E65, 2019 | 35 | 2019 |
| A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions N Foroutan, JE Tarride, F Xie, M Levine Clinicoeconomics and Outcomes Research, 821-854, 2018 | 26 | 2018 |
| “Budget Impact Analyses”: A Practical Policy Making Tool for Drug Reimbursement Decisions HR Jamshidi, N Foroutan, J Salamzadeh Iranian Journal of Pharmaceutical Research: IJPR 13 (3), 1105, 2014 | 13 | 2014 |
| Costs of treatment after renal transplantation: is it worth to pay more? J Salamzadeh, N Foroutan, HR Jamshidi, HR Rasekh, AR Gatari, ... Iranian Journal of Pharmaceutical Research: IJPR 13 (1), 271, 2014 | 12 | 2014 |
| Budget impact analysis of conversion from cyclosporine to sirolimus as immunosuppressive medication in renal transplantation therapy N Foroutan, HR Rasekh, J Salamzadeh, HR Jamshidi, M Nafar ClinicoEconomics and Outcomes Research, 545-553, 2013 | 7 | 2013 |
| A comparison of pharmaceutical budget impact analysis (BIA) recommendations amongst the Canadian patented medicine prices review board (PMPRB), public and private payers N Foroutan, JE Tarride, F Xie, F Mills, M Levine PharmacoEconomics-Open 3 (4), 437-451, 2019 | 6 | 2019 |
| Budget impact analysis of using omeprazole immediate-release oral suspension in replace of intravenous pantoprazole in critically ill patients N Foroutan, F Fahimi, Y Dabiri, A Foroutan, M Habibi, J Salamzadeh J Popul Ther Clin Pharmacol 22 (3), 2015 | 3 | 2015 |
| Stakeholders' feedback on the proposed recommendations for updating the patented medicine prices review board (pmprb) budget impact analysis guidelines. N Foroutan, JE Tarride, F Xie, B Jameel, F Mills, M Levine Journal of Population Therapeutics and Clinical Pharmacology= Journal de la …, 2020 | 2 | 2020 |
| Proposals for updating the Canadian Patented Medicine Prices Review Board pharmaceutical budget impact analysis guidelines for new drug submissions to public and private payers N Foroutan | 1 | 2019 |
| PP51 updating Canadian pharmaceutical budget impact analysis guidelines N Foroutan, M Levine, JE Tarride, F Xie International Journal of Technology Assessment in Health Care 34 (S1), 86-86, 2018 | 1 | 2018 |
| PRM18 Conducting Pharmaceutical Budget Impact Analyses in Iran: In Accordance With ISPOR Task Force Report on Good Practice for Budget Impact Analysis N Foroutan, HR Jamshidi, J Salamzadeh, A Foroutan, H Rasekh Value in Health 15 (7), A463, 2012 | 1 | 2012 |
| PDG5 Changes in Canadian Guidelines for Conducting Budget IMPACT Analysis N Bosnic, Y Zhang, N Foroutan Value in Health 24, S87, 2021 | | 2021 |
| Comparative effectiveness and safety of interventions for acute diarrhoea and gastroenteritis in children: A systematic review and network meta-analysis. ID Flórez Gómez, JJ Yepes Núñez, JM Sierra Abaunza, AM Zea, ... Public Library of Science, 2018 | | 2018 |
| Financial impacts of using Omeprazole oral suspension for preventing upper Gastrointestinal bleeding early after Intensive Care admission N Foroutan, A Foroutan Value in Health 18 (3), A224, 2015 | | 2015 |
| Costs of Treatment after Renal Transplantation: Is it Worth to Pay More? N Foroutan Brieflands, 2014 | | 2014 |
| Cost of Treatment After Renal Transplantation in Iran: Should Government Continue Paying for New Expensive Immunosuppressive Drugs? N Foroutan, J Salamzadeh, A Foroutan, HR Jamshidi, H Rasekh Value in Health 16 (7), A632, 2013 | | 2013 |
| A standard model of conducting pharmaceutical budget impact analyses for drug reimbursement in Iran N Foroutan, H Jamshidi, J Salamzadeh, A Foroutan, H Rasekh Research in Pharmaceutical Sciences 7 (5), 996, 2012 | | 2012 |
